In our study, Claudin-4 was poorly significantly associated with molecular subtypes of breast cancer, and Sara Ricardo’s study showed that a single IHC for Claudin-4 is not sufficient to assess and identify molecular subtypes of breast cancer and that additional markers, such as CSC (cancer stem cell) markers, are needed to improve subgroup identification [31]. Here, CLDN4 is linked to breast cancer.